Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Nabriva Therapeutics AG (NBRVF) had Revenue of $36.94M for the most recently reported fiscal year, ending 2022-12-31.

Quarterly Annual

Figures for fiscal year ending 2022-12-31

Income Statement Financials
Revenue	$36.94M
Net Income	$-57.19M
Cost of Goods Sold	$28.58M
Gross Profit	$8.35M
Operating Expenses	$92.42M
Operating Income	$-55.49M
Non-Operating Income/Expense	$-0.13M
Pre-Tax Income	$-55.62M
Normalized Pre-Tax Income	$-55.62M
Income after Taxes	$-57.19M
Income from Continuous Operations	$-57.19M
Consolidated Net Income/Loss	$-57.19M
Normalized Income after Taxes	$-57.19M
EBIT	$-55.49M
EBITDA	$-55.27M
Weighted-Average Shares Outstanding (Basic)	26.82M
Weighted-Average Shares Outstanding (Diluted)	26.82M
Earnings per Share (EPS) (Basic)	$-2.13
Earnings per Share (EPS) (Diluted)	$-2.13
Balance Sheet Financials
Current Assets	$31.10M
Property, Plant, and Equipment	$0.28M
Long-Term Assets	$0.66M
Total Assets	$31.77M
Current Liabilities	$27.61M
Long-Term Debt	$0.39M
Long-Term Liabilities	$0.87M
Total Liabilities	$28.47M
Common Equity	$3.29M
Tangible Shareholders Equity	$3.29M
Shareholders Equity	$3.29M
Common Shares Outstanding	32.01M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-36.71M
Cash Flow from Investing Activities	$-0.26M
Cash Flow from Financial Activities	$1.85M
Beginning Cash	$47.83M
End Cash	$12.54M
Increase/Decrease in Cash	$-35.30M
Stock-Based Compensation	$1.97M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.13
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.11
Debt to Equity Ratio	1.59
Gross Margin	22.62%
Operating Margin	-150.24%
EBIT Margin	-150.24%
EBITDA Margin	-149.65%
Pre-Tax Profit Margin	-150.58%
Profit Margin	-154.83%
Free Cash Flow	$-36.92M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	1.16
Inventory Turnover	2.95
Receiveable Turnover	5.48
Days Sales in Receivables	66.63
Return on Equity	-1736.60%
Return on Tangible Equity	-1738.15%
Return on Assets	-180.03%
Return on Investments	-1553.52%
Book Value Per Share	$0.10
Free Cash Flow per Share	$-1.38
Operating Cash Flow per Share	$-1.37

Data from Zacks Investment Research, Inc.